<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">ChemMedChem</journal-id><journal-id journal-id-type="iso-abbrev">ChemMedChem</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>ChemMedChem</journal-title></journal-title-group><issn pub-type="ppub">1860-7179</issn><issn pub-type="epub">1860-7187</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8571052</article-id><article-id pub-id-type="pmcid-ver">PMC8571052.1</article-id><article-id pub-id-type="pmcaid">8571052</article-id><article-id pub-id-type="pmcaiid">8571052</article-id><article-id pub-id-type="manuscript-id">NIHMS1734488</article-id><article-id pub-id-type="pmid">34329530</article-id><article-id pub-id-type="doi">10.1002/cmdc.202100325</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1734488</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1734488</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Investigation of the effects and mechanisms of anticancer action of a Ru(II)-arene iminophosphorane compound in triple negative breast cancer cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Nayeem</surname><given-names initials="N">Nazia</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yeasmin</surname><given-names initials="A">Arefa</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cobos</surname><given-names initials="SN">Samantha N.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Younes</surname><given-names initials="A">Ali</given-names><prefix>Dr.</prefix></name><xref ref-type="aff" rid="A4">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hubbard</surname><given-names initials="K">Karen</given-names><prefix>Prof.</prefix></name><xref ref-type="aff" rid="A3">c</xref><xref ref-type="aff" rid="A5">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Contel</surname><given-names initials="M">Maria</given-names><prefix>Prof.</prefix></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref><xref ref-type="aff" rid="A3">c</xref></contrib></contrib-group><aff id="A1"><label>a</label>Department of Chemistry, and Brooklyn College Cancer Center, Brooklyn College, The City University of New York, Brooklyn, NY, 11210 (USA)</aff><aff id="A2"><label>b</label>Department of Chemistry, and Brooklyn College Cancer Center, Brooklyn College, The City University of New York, Brooklyn, NY, 11210 (USA)</aff><aff id="A3"><label>c</label>Biology, Chemistry, and Biochemistry PhD Programs, The Graduate Center, The City University of New York, New York, New York, 10016 (USA)</aff><aff id="A4"><label>d</label>Department of Chemistry, Hunter College, The City University of New York, 695 Park Avenue, New York, NY, 10065 (USA)</aff><aff id="A5"><label>e</label>Biology Department, The City College of New York, The City University of New York, 160 Covent Avenue, New York, NY, 10031 (USA)</aff><author-notes><fn id="FN1"><p id="P1">Dedicated to Prof. Adoraci&#243;n G&#243;mez-Quiroga, cancer survivor and outstanding medicinal inorganic chemist.</p></fn><fn id="FN2"><p id="P2">Institute and/or researcher Twitter usernames: @ContelLab, @NazNayeem</p></fn><corresp id="CR1"><email>MariaContel@brooklyn.cuny.edu</email>, Homepage: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://mariacontel.blog.brooklyn.cuny.edu/">http://mariacontel.blog.brooklyn.cuny.edu/</ext-link></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>8</month><year>2021</year></pub-date><pub-date pub-type="ppub"><day>05</day><month>11</month><year>2021</year></pub-date><volume>16</volume><issue>21</issue><issue-id pub-id-type="pmc-issue-id">393313</issue-id><fpage>3280</fpage><lpage>3292</lpage><pub-history><event event-type="nihms-submitted"><date><day>04</day><month>09</month><year>2021</year></date></event><event event-type="pmc-release"><date><day>05</day><month>11</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>05</day><month>11</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-11 15:25:13.220"><day>11</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1734488.pdf"/><abstract id="ABS1"><p id="P3">Triple negative breast cancer (TNBC) is one of the breast cancers with poorer prognosis and survival rates. TNBC has a disproportionally high incidence and mortality in women of African descent. We report on the evaluation of Ru-IM (<bold>1</bold>), a water-soluble organometallic ruthenium compound, in TNBC cell lines derived from patients of European (MDA-MB-231) and African (HCC-1806) ancestry (including IC<sub>50</sub> values, cellular and organelle uptake, cell death pathways, cell cycle, effects on migration, invasion, and angiogenesis, a preliminary proteomic analysis, and an NCI 60 cell-line panel screen). <bold>1</bold> was previously found highly efficacious in MDA-MB-231 cells and xenografts, with little systemic toxicity and preferential accumulation in the tumor. We observe a similar profile for this compound in the two cell lines studied, which includes high cytotoxicity, apoptotic behavior and potential antimetastatic and antiangiogenic properties. Cytokine M-CSF, involved in the PI3/AKT pathway, shows protein expression inhibition with exposure to <bold>1</bold>. We also demonstrate a p53 independent mechanism of action.</p></abstract><abstract id="ABS2" abstract-type="graphical"><title>Graphical Abstract</title><p id="P4">
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="nihms-1734488-f0010.jpg"/>
</p><p id="P5">First preclinical attempt to assess health disparities in triple negative breast cancer treatments by using an organometallic compound (Ru-IM). Its evaluation in TNBC cell lines derived from patients of European (MDA-MB-231) and African (HCC-1806) descent affords a similar profile, displaying high cytotoxicity, apoptotic behavior and potential antimetastatic and antiangiogenic properties, plausibly involving the PI3/AKT pathway.</p></abstract><kwd-group><kwd>Ruthenium</kwd><kwd>Triple Negative Breast Cancer</kwd><kwd>Health Disparities</kwd><kwd>Antimetastatic</kwd><kwd>Antiangiogenic</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>